Abstract
Background: Long-term pacing is frequently necessary in patients with congenital heart disease (CHD). Preservation of ventricular function and avoidance of venous occlusion is important in these patients. Site-selective pacing with a smaller diameter lead is achievable with the model 3830 lead (SelectSecure(R), Medtronic Inc., Minneapolis, MN, USA), which was specifically designed to target these complications. We describe our initial experience with the Model 3830 lead in patients with CHD. Methods: Retrospective analysis of all patients undergoing site-selective implantation of a Model 3830 lead(s) from two congenital heart centers (Bristol, UK, and Dublin, Ireland) from October 2004 until February 2008. Results: We implanted 139 SelectSecure(R) leads (atrial n = 70; ventricular n = 69) in 90 patients (57 male) with CHD. Median age at implantation: 13.4 years (1.1-59.2 years), median weight: 43 kg. Sixty-nine patients (76%) were children (
Translated title of the contribution | Initial Experience of Pacing with a Lumenless Lead System in Patients with Congenital Heart Disease |
---|---|
Original language | English |
Pages (from-to) | 1428 - 1433 |
Number of pages | 6 |
Journal | Pacing and Clinical Electrophysiology |
Volume | 32(11) |
Publication status | Published - Nov 2009 |